TSC-201-B0702

N/A

Report date: 2024/04/28 20:00:08

Base Information

Drug NameTSC-201-B0702
Drug Alias NameTSC-201-B0702
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionCell replacementsMelanoma-associated antigen C2 modulators
TargetsMelanoma-associated antigen C2
Therapy Area/IndicationsPenile NeoplasmsVulvar NeoplasmsUterine Cervical Neoplasms +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTScan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTScan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPenile NeoplasmsVulvar NeoplasmsUterine Cervical Neoplasms +[15] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A